Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -84M | -58M | -45M | -33M | -16M |
| EBITDA | -71M | -56M | -41M | -31M | -8M |
| Net Income | -74M | -58M | -43M | -32M | -9M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$30.02
-0.13% today
1Y Change
+56.75%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tectonic Therapeutic, Inc. (TECX) is a Healthcare stock with a market cap of $550.00M and listed on NASDAQ. The stock last traded around $30.02 and up 56.7% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -3.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -3.1%, free cash flow -1.8% with operating margin 0.0% and ROIC -33.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TECX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TECX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TECX Max Drawdown
-44.62%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TECX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$8.9M
+72.3% YoY
Free Cash Flow
-$14.6M
+85.0% YoY
Revenue Growth
+0.0%
EPS Growth
-3.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -84M | -58M | -45M | -33M | -16M |
| EBITDA | -71M | -56M | -41M | -31M | -8M |
| Net Income | -74M | -58M | -43M | -32M | -9M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 254M | 141M | 29M | 36M | 28M |
| Total Assets | 261M | 153M | 39M | 47M | 33M |
| Total Liabilities | 10M | 12M | 124M | 93M | 48M |
| Shareholder Equity | 251M | 141M | -85M | -46M | -15M |
| Total Debt | 1M | 3M | 4M | 6M | 1M |
| Net Debt | -253M | -138M | -24M | -30M | -27M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
12M
+87.2% YoY
Capital Expenditures
2M
-694.8% YoY
Free Cash Flow
15M
+85.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-26.9%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.